DOCSLIB.ORG

Combined Index to USP 43 and NF 38, Volumes 1–5

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combined Index to USP 43 and NF 38, Volumes 1–5 Combined Index to USP 43 and NF 38 Abaca-Acety I-1 Combined Index to USP 43 and NF 38, Volumes 1±5 Page citations refer to the pages of Volumes 1, 2, 3, 4 and 5 of USP 43±NF 38. This index is repeated in its entirety in each volume. 1±2482 Volume 1 2483±4722 Volume 2 4723±6108 Volume 3 6109±7208 Volume 4 7209±8760 Volume 5 Numbers in angle brackets such as 〈421〉 refer to chapter numbers in the General Chapters section. and (salts of) chlorpheniramine, and tramadol hydrochloride oral A dextromethorphan, and suspension, 4452 pseudoephedrine, capsules containing at Acetanilide, 6132 Abacavir least three of the following, 52 Acetate oral solution, 19 and (salts of) chlorpheniramine, methyl, 6178 sulfate, 23 dextromethorphan, and Acetate buffer, 6145 tablets, 20 pseudoephedrine, oral powder TS, 6225 and lamivudine tablets, 21 containing at least three of the Acetazolamide, 73 Abiraterone following, 54 for injection, 74 acetate, 25 and (salts of) chlorpheniramine, oral suspension, 76 acetate tablets, 26 dextromethorphan, and tablets, 76 Absolute pseudoephedrine, oral solution Acetic acid, 5599, 6132 alcohol, 6133 containing at least three of the ammonium acetate buffer TS, 6225 ether, 6131 following, 56 diluted, 5599, 6132, 6159 Absorbable and (salts of) chlorpheniramine, double-normal (2 N), 6238 dusting powder, 1569 dextromethorphan, and glacial, 77, 6132, 6168 gelatin film, 2092 pseudoephedrine, tablets containing at glacial, TS, 6229 gelatin sponge, 2093 least three of the following, 58 and hydrocortisone otic solution, 2235 surgical suture, 4189 chlorpheniramine maleate, and irrigation, 78 Absorbent dextromethorphan hydrobromide metaphosphoric, TS, 6231 cotton, 6132 tablets, 60 otic solution, 78 gauze, 2091 and codeine phosphate capsules, 52 strong, TS, 6225 Acacia, 5597 and codeine phosphate oral solution, 54 1 M TS, 6225 syrup, 5597 and codeine phosphate oral suspension, 2 M TS, 6225 Acamprosate calcium, 28 56 Acetic acid in peptides, 6741 Acarbose, 30 and codeine phosphate tablets, 66 0.008 M Acetic acid TS, 6225 tablets, 31 dextromethorphan hydrobromide, 0.3 N Acetic acid TS, 6225 Acebutolol hydrochloride, 33 doxylamine succinate, and Acetic anhydride, 6132 capsules, 35 pseudoephedrine hydrochloride oral Acetohydroxamic acid, 78 Acepromazine maleate, 36 solution, 67 tablets, 79 injection, 37 and diphenhydramine citrate tablets, 69 Acetone, 5600, 6132 tablets, 38 diphenhydramine hydrochloride, and anhydrous, 6132 Acesulfame potassium, 5598 pseudoephedrine hydrochloride tablets, neutralized, 6132, 6227 Acetal, 6132 70 Acetonitrile, 6132 Acetaldehyde, 6132 and hydrocodone bitartrate tablets, 2224 spectrophotometric, 6132 TS, 6225 isometheptene mucate, and Acetophenone, 6132 Acetaldehyde ammonia trimer trihydrate, dichloralphenazone capsules, 2423 p-Acetotoluidide, 6132 6132 and oxycodone capsules, 3341 Acetylacetone, 6132 Acetaminophen, 38 and oxycodone tablets, 3343 Acetyl chloride, 6132 aspirin and caffeine tablets, 49 and pentazocine tablets, 3460 Acetylcholine chloride, 80, 6132 and aspirin tablets, 48 and pseudoephedrine hydrochloride for ophthalmic solution, 81 butalbital and caffeine capsules, 645 tablets, 72 Acetylcysteine, 82 butalbital and caffeine tablets, 646 oral solution, 41 Acetylcysteine and caffeine tablets, 51 for effervescent oral solution, 42 compounded solution, 83 capsules, 40 suppositories, 44 and isoproterenol hydrochloride inhalation oral suspension, 42 solution, 84 tablets, 45 extended-release tablets, 47 I-2 Acety-Alumi Combined Index to USP 43 and NF 38 Acetylcysteine (continued) Agar, 5603, 6133 pyrogallol TS, 6234 solution, 82 Agarose, 6133 sodium hydrosulfite TS, 6226 N-Acetylglucosamine, 4745 Air, medical, 100 Alkaline borate buffer, 6145 2-Acetylresorcinol, 6133 Air-helium certified standard, 6133 Alkaline cupric tartrate TS, 6226 3-Acetylthio-2-methylpropanoic acid, 6133 Alanine, 101 Alkyl (C12-15) benzoate, 5609 Acetyltributyl citrate, 5601 L-Alanyl-L-glutamine, 4748 Alkylphenoxypolyethoxyethanol, 6134 Acetyltriethyl citrate, 5601 Albendazole, 102 Allantoin, 130 N-Acetyltyrosine, 4746 oral suspension, 102 Allopurinol, 131 N-Acetyl-L-tyrosine ethyl ester, 6133 tablets, 103 oral suspension, 133 Acid Albumen TS, 6225 tablets, 134 acrylic, 6133 Albumin Allyl isothiocyanate, 135 alpha lipoic, 5124 bovine serum, 6133 Almond oil, 5609 dehydroacetic, 5741 human, 104 Almotriptan ferric chloride TS, 6225 rAlbumin human, 5604 tablets, 138 ferrous sulfate TS, 6225 Albuterol, 104 Almotriptan malate, 135 Folic, compounded oral soultion, 2027 sulfate, 109 Aloe, 140 iminodiacetic, 6172 tablets, 105 Alosetron stannous chloride TS, 6225 extended-release tablets, 106 tablets, 142 stannous chloride TS, stronger, 6225 Alclometasone dipropionate, 110 Alosetron hydrochloride, 141 Acid-neutralizing capacity 〈301〉, 6661 cream, 111 Alpha Acidulated phosphate and sodium fluoride ointment, 112 lipoic acid, 5124 topical solution, 4074 Alcohol, 113, 6133 Alpha-chymotrypsin, 6134 Acitretin, 85 70 percent, 80 percent, and 90 percent, Alpha cyclodextrin hydrate, 6134 capsules, 86 6133 Alpha-(2-(methylamino)ethyl)benzyl alcohol, Acoustic emission 〈1005〉, 7230, 7644, 8117 absolute, 6133 6134 Acrylic acid, 6133 aldehyde-free, 6134 Alphanaphthol, 6134 Activated alpha-(2-(methylamino)ethyl)benzyl, 6134 Alphazurine 2G, 6220 alumina, 6133 amyl, 6134 Alprazolam, 144 charcoal, 923, 6133 tert-amyl, 6134, 6137, 6173 oral suspension, 145 magnesium silicate, 6133 butyl, 5648 tablets, 146 Acyclovir, 88 dehydrated, 115, 6134, 6155 extended-release tablets, 148 capsules, 89 dehydrated isopropyl, 6134 orally disintegrating tablets, 152 for injection, 90 denaturated, 6134 Alprenolol hydrochloride, 6134 ointment, 91 denaturated, TS, 6228 Alprostadil, 154 oral suspension, 92 determination 〈611〉, 6848 injection, 156 tablets, 92 in dextrose injection, 117 Alteplase, 157 Adamantane, 6133 diluted, 5607, 6134 for injection, 160 Adapalene, 93 injection, dehydrated, 117 Alternative microbiological sampling methods gel, 96 isobutyl, 6134 for nonsterile inhaled and nasal products Ademetionine disulfate tosylate, 4747 isopropyl, 6134 〈610〉, 6846 Adenine, 97 methyl, 6134 Altretamine, 163 sulfate, 6133 neutralized, 6134, 6182 capsules, 164 Adenosine, 98 phenol TS, 6225 Alum, 6134 injection, 99 n-propyl, 6134 ammonium, 165, 6134 Adipic acid, 5602, 6133 rubbing, 118 potassium, 166, 6192 Admissions secondary butyl, 6134 Alumina, 6134 to NF 38, tertiary butyl, 6134 activated, 6133, 6134, 6138 to USP 43, xxxi Alcoholic anhydrous, 6134 ammonia TS, 6225 aspirin, codeine phosphate, and magnesia mercuric bromide TS, 6226 tablets, 404 potassium hydroxide TS, 6226 aspirin, and magnesia tablets, 397 potassium hydroxide TS 2, 6234 aspirin, and magnesium oxide tablets, 399 Aerosol TS, 6225 magnesia, and calcium carbonate Bacitracin and polymyxin B sulfate topical, Alcoholic potassium hydroxide chewable tablets, 169 468 0.2 N VS, 6238 magnesia, calcium carbonate, and Benzocaine, butamben, and tetracaine Alcoholometric table, 6346 simethicone chewable tablets, 170 hydrochloride topical, 513 Aldehyde dehydrogenase, 6134 magnesia, and calcium carbonate oral Benzocaine and menthol topical, 518 Alendronate sodium, 119 suspension, 168 Benzocaine topical, 503 tablets, 120 magnesia, and simethicone oral Fluticasone propionate and salmeterol Alfadex, 5607 suspension, 173 inhalation, 2005 Alfentanil magnesia, and simethicone chewable Fluticasone propionate inhalation, 1988 hydrochloride, 122 tablets, 174 Inhalation and nasal drug products: injection, 123 and magnesia oral suspension, 166 aerosols, sprays, and powdersÐ Alfuzosin hydrochloride, 124 and magnesia tablets, 167 performance quality tests 〈601〉, 6819 extended-release tablets, 125 magnesium carbonate, and magnesium Isoproterenol sulfate inhalation, 2437 Alginates assay 〈311〉, 6662 oxide tablets, 178 Lidocaine topical, 2622 Alginic acid, 5608 and magnesium carbonate oral suspension, Polymyxin B sulfate and bacitracin zinc Alizarin complexone, 6134 176 topical, 3591 Alkaline and magnesium carbonate tablets, 177 Povidone±iodine topical, 3635 cupric citrate TS, 6226 and magnesium trisilicate oral suspension, Thimerosal topical, 4346 cupric citrate TS 2, 6226 179 Tolnaftate topical, 4425 cupric iodide TS, 6226 and magnesium trisilicate tablets, 180 Triamcinolone acetonide topical, 4483 mercuric-potassium iodide TS, 6226 Aluminon, 6134 phosphatase enzyme, 6134 Aluminum, 6135 picrate TS, 6226 acetate topical solution, 181 Combined Index to USP 43 and NF 38 Alumi-Ammon I-3 Aluminum (continued) Amiloride hydrochloride, 222 valsartan and hydrochlorothiazide tablets, chloride, 181 and hydrochlorothiazide tablets, 224 279 chlorohydrate, 182 tablets, 223 Amlodipine and atorvastatin chlorohydrate solution, 183 Amiloxate, 227 tablets, 265 chlorohydrex polyethylene glycol, 184 Aminoacetic acid, 6135 Amlodipine besylate, 285 chlorohydrex propylene glycol, 185 4-Aminoantipyrine, 6135 tablets, 286 dichlorohydrate, 185 Aminobenzoate Ammonia dichlorohydrate solution, 186 potassium, 228 alcoholic TS, 6225 dichlorohydrex polyethylene glycol, 187 potassium capsules, 230 detector tube, 6136 dichlorohydrex propylene glycol, 188 sodium, 231 N 13 injection, 3183 hydroxide gel, 188 Aminobenzoic acid, 233 nitrate TS, silver, 6234 hydroxide gel, dried, 189 gel, 234 solution, diluted, 6136 hydroxide gel capsules, dried, 190 p-Aminobenzoic acid, 6135 solution, strong, 5616 hydroxide gel tablets, dried, 190 2-Aminobenzonitrile, 6135 spirit, aromatic, 287 monostearate, 5612 Aminocaproic acid, 235 TS, 6136, 6226 oxide, 5613 injection, 236 TS 2, 6226
Load more

Recommended publications
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
    [Show full text]
  • Insomnia and Anxiety in Older People Sleeping Pills Are Usually Not the Best Solution
    ® Insomnia and anxiety in older people Sleeping pills are usually not the best solution lmost one-third of older people in the people who take one of United States take sleeping pills. These these medicines sleep medicines are also sometimes called only a little longer and A“sedative-hypnotics” or “tranquilizers.” They better than those who affect the brain and spinal cord. don’t take a medicine. Doctors prescribe some of these medicines Sleeping pills can for sleep problems. Some of these medicines have serious side effects. also can be used to treat other conditions, such All sedative-hypnotic medicines have special as anxiety or alcohol withdrawal. Sometimes, risks for older adults. Seniors are likely to be doctors also prescribe certain anti-depressants more sensitive to the medicines’ effects than for sleep, even though that’s not what they’re younger adults. And these medicines may designed to treat. stay in older people’s bodies longer. These Most older adults should first try to treat their medicines can cause confusion and memory insomnia without medicines. According to the problems that: American Geriatrics Society, there are safer and • Increase the risk of falls and hip fractures. better ways to improve sleep or reduce anxiety. These are common causes of hospital stays Here’s why: and death in older people. Sleeping pills may not help much. • Increase the risk of car accidents. Many ads say that sleeping pills help people get a full, restful night’s sleep. But studies show that this is not exactly true in real life. On average, The new “Z” medicines also have risks.
    [Show full text]
  • Drug & Alcohol Testing Program
    Pottawattmie County Drug & Alcohol Testing Program Appendix A Table of Contents POLICY STATEMENT ...................................................................................................................................... 3 SCOPE ............................................................................................................................................................ 4 EDUCATION AND TRAINING .......................................................................................................................... 4 DESIGNATED EMPLOYER REPRESENTATIVE (DER): ....................................................................................... 5 DUTY TO COOPERATE ................................................................................................................................... 5 EMPLOYEE ADMISSION OF ALCOHOL AND CONTROLLED SUBSTANCE USE: (49 CFR Part 382.121) ... 6 PROHIBITED DRUGS AND ILLEGALLY USED CONTROLLED SUBSTANCES: ..................................................... 7 PROHIBITED BEHAVIOR AND CONDUCT: ...................................................................................................... 8 DRUG & ALCOHOL TESTING REQUIREMENTS (49 CFR, Part 40 & 382) ............................................... 10 DRUG & ALCOHOL TESTING CIRCUMSTANCES (49 CFR Part 40 & 382) .............................................. 12 A. Pre-Employment Testing: .................................................................................................... 12 B. Reasonable Suspicion Testing: .........................................................................................
    [Show full text]
  • Compositions Comprising Drospirenone Molecularly
    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Drospirenone-Containing Birth Control Pills (Yaz, Yasmin, Ocella, Gianvi and Their Generics)
    Drospirenone-Containing Birth Control Pills (Yaz, Yasmin, Ocella, Gianvi and their generics) Drospirenone is a progestin component of some birth control pills that does some blocking of testosterone (the "male hormone" that women have, too, and the hormone that can be a part of making acne worse). This is why drospirenone-containing birth control pills are especially good at helping acne (and why they can theoretically help hirsutism and female-pattern scalp hair loss as well). Drospirenone is also a mild diuretic and is why these birth control pills do not cause the water weight gain that some birth control pills can. Any birth control pill can theoretically help acne just by evening out hormonal fluctuations, but for many birth control pills, the effects on acne is very minimal. Which birth control pills are most likely to help acne? Some birth control pills are more like testosterone and some are less like testosterone. The ones that are less like testosterone can theoretically help acne more. The drospirenone-containing birth control pills go one step further by blocking testosterone, and may show the most benefit on clearing acne. Drospirenone is a progestin that is derived from 17-alpha-spironolactone and is chemically related to the diuretic spironolactone. Spironolactone is a diuretic (used for high blood pressure) that is sometimes used off-label for the treatment of acne, hirsutism or female-pattern hair loss. Often people say that a drospirenone-containing birth control pill may be equivalent to 25mg of spironolactone. Risks : Any estrogen-containing birth control pill increases the risk of a high blood pressure, stroke, or other life-threatening blood clot, and one study showed possibly a slightly higher risk with a drospirenone-containing birth control pill.
    [Show full text]
  • Betamethasone Valerate Foam: a Look at the Clinical Data
    Review: Clinical Trial Outcomes Betamethasone valerate foam: a look at the clinical data Clin. Invest. (2014) 4(3), 259–267 Topical corticosteroids and especially betamethasone valerate (BMV) have Avner Shemer1, Nicole Sakka1 & been used topically to relieve many inflammatory skin conditions such as Dov Tamarkin*2 psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs 1Department of Dermatology, the Chaim Sheba Medical Center, Affiliated with the can influence the performance of these topical applications. BMV has Tel-Aviv University, Sackler School of Medicine, traditionally been available in creams, ointments, lotions and sprays. In Tel Hashomer, Israel the early 2000s, a topical hydroethanolic BMV foam became commercially 2Foamix Ltd., 2 Holzman Street, Weizmann available. Subsequently, alcohol-free emulsion- and petrolatum-based Science Park, Rehovot 76704, Israel foam formulations were also developed. This manuscript reviews the *Author for correspondence: Tel.: +972 52 457 5677 properties of BMV foams and clinical studies that have been conducted Fax: +972 8 853 1102 to assess their efficacy and safety as treatments for scalp and non-scalp [email protected] psoriasis, as well as other dermatological inflammatory conditions. Keywords: betamethasone valerate • foam • psoriasis • topical corticosteroids Topical corticosteroids have been ranked in four groups consisting of seven classes ranging from ultra-high potency preparations (class 1) to low-potency prepara- tions (class 7). Betamethasone valerate (BMV) is a mid-potency corticosteroid (class 3–5, depending on the dosage form), used topically to relieve inflammatory skin conditions. It is used as a treatment for psoriasis, atopic dermatitis and other corticosteroid-responsive dermatoses. The vehicle used to deliver topical drugs can influence the performance of these drugs.
    [Show full text]
  • Albany-Molecular-Research-Regulatory
    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
    [Show full text]
  • Neonatal Intensive Care Drug Therapy Update: a Bibliography
    LWW/JPNN AS310-13 July 28, 2004 23:11 Char Count= 0 J Perinat Neonat Nurs Vol. 18, No. 3, pp. 292–306 c 2004 Lippincott Williams & Wilkins, Inc. Neonatal Intensive Care Drug Therapy Update: A Bibliography Jason Sauberan, PharmD BIBLIOGRAPHY I. Overview A. Clark RH, Bloom BT, Gerstmann DR Medications Used in Neonatal Intensive Care Units—A Descriptive Study [abstract 3047]. In: Program and abstracts of the 2004 Pediatric Academic Societies’ Annual Meeting, San Francisco, CA. B. Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002 Feb;19(2):67–72. C. O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002 Nov;110(5):e52. D. Committee on Drugs. American Academy of Pediatrics. Uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002 Jul;110(1 Pt 1):181–3. II. Anti-infectives A. Linezolid 1. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S158–63. 2. Vo M, Cirincione BB, Rubino CM, Jungbluth GL. Pharmacokinetics of Linezolid in Neonates and Young Infants [abstract A-1409]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
    [Show full text]
  • Effect of Aminophylline on Diaphragmatic Contractility in the Piglet
    003 1-3998/90/2803-0196$02.00/0 PEDIATRIC RESEARCH Vol. 28, No. 3, 1990 Copyright 0 1990 International Pediatric Research Foundation, Inc. Printed in (I.S.A. Effect of Aminophylline on Diaphragmatic Contractility in the Piglet DENNIS E. MAYOCK, THOMAS A. STANDAERT, JON F. WATCHKO, AND DAVID E. WOODRUM1 University of Washington School of Medicine, Department of Pediatrics, Division of Neonatal and Respiratory Diseases, Seattle, Washington 98195 ABSTRACT. Minute ventilation, arterial blood gases, ar- of arterial oxygen > 8 kPa (60 torr) in room air, and a partial terial pH, cardiac output, and transdiaphragmatic force pressure of the arterial carbon dioxide 5 6.7 kPa (50 torr) were generation, both during spontaneous ventilation and in accepted for study. The animals were anesthetized with an i.v. response to phrenic nerve stiwulation during airway occlu- combination of chloralose (30 mg/kg) and urethane (1 50 mg/ sion at end expiration, were measured in nine anesthetized, kg) and studied in the supine position. Subsequent infusions of tracheostomized piglets before and 30 min after parenteral anesthetic were used if the piglet developed jaw clonus. A trache- infusion of 20 mg/kg aminophylline. Serum theophylline ostomy was placed and connected to a two-way nonrebreathing levels averaged 109 f 21 ~mol/L(19.7 f 3.7 ~g/mL)at valve (model 2384, Hans Rudolph, Inc., Kansas City, MO). 30 min postinfusion. No significant changes were noted in Inspiratory flow was detected by a hot-wire anemometer and pH, blood gases, blood Pressure, or ventilatory measures integrated to provide tidal volume. All animals breathed 50% after aminophylline.
    [Show full text]
  • Aminophylline Catalog Number A1755 Storage
    Aminophylline Catalog Number A1755 Storage Temperature –20 °C Replacement for Catalog Number 216895 CAS RN 317-34-0 Storage/Stability Synonyms: theophylline hemiethylenediamine complex; Aminophylline should be kept tightly closed to prevent 3,7-dihydro-1,3-demethyl-1H-purine-2,6-dione CO2 absorption from the atmosphere, which leads to compound with 1,2-ethanediamine (2:1); formation of theophylline and decreased solubility in 1,2 3 (theophylline)2 • ethylenediamine aqueous solutions. Stock solutions should be protected from light and prevented from contact with Product Description metals.2 Molecular Formula: C7H8N4O2 ·1/2 (C2H8N2) Molecular Weight: 210.3 References 1. The Merck Index, 12th ed., Entry# 485. Aminophylline is a xanthine derivative which is a 2. Martindale: The Extra Pharmacopoeia, 31st ed., combination of theophylline and ethylenediamine that is Reynolds, J. E. F., ed., Royal Pharmaceutical more water soluble than theophylline alone. Society (London, England: 1996), pp. 1651-1652. Aminophylline has been widely used as an inhibitor of 3. Data for Biochemical Research, 3rd ed., Dawson, cAMP phosphodiesterase.3 R. M. C., et al., Oxford University Press (New York, NY: 1986), pp. 316-317. Aminophylline has been shown to limit 4. Pelech, S. L., et al., cAMP analogues inhibit phosphatidylcholine biosynthesis in cultured rat phosphatidylcholine biosynthesis in cultured rat hepatocytes.4 It has been used in studies of acute hepatocytes. J. Biol. Chem., 256(16), 8283-8286 hypoxemia in newborn and older guinea pigs.5 The (1981). effect of various xanthine derivatives, including 5. Crisanti, K. C., and Fewell, J. E., Aminophylline aminophylline, on activation of the cystic fibrosis alters the core temperature response to acute transmembrane conductance regulator (CFTR) chloride hypoxemia in newborn and older guinea pigs.
    [Show full text]
  • Rosemary)-Derived Ingredients As Used in Cosmetics
    Safety Assessment of Rosmarinus Officinalis (Rosemary)-Derived Ingredients as Used in Cosmetics Status: Tentative Amended Report for Public Comment Release Date: March 28, 2014 Panel Meeting Date: June 9-10, 2014 All interested persons are provided 60 days from the above release date to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Director, Dr. Lillian J. Gill. The 2014 Cosmetic Ingredient Review Expert Panel members are: Chairman, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, D.P.A. This safety assessment was prepared by Monice M. Fiume, Assistant Director/Senior Scientific Analyst. © Cosmetic Ingredient Review 1620 L Street, NW, Suite 1200♢ Washington, DC 20036 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] TABLE OF CONTENTS Abstract ......................................................................................................................................................................................................................................
    [Show full text]
  • Antiluteogenic Effects of Serial Prostaglandin F2α Administration in Mares
    ANTILUTEOGENIC EFFECTS OF SERIAL PROSTAGLANDIN F2α ADMINISTRATION IN MARES Thesis Presented in partial fulfillment of the requirements for the Master of Science in the Graduate School of The Ohio State University Elizabeth Ann Coffman Graduate ProGram in Comparative and Veterinary Medicine The Ohio State University 2013 Thesis committee: Carlos R.F. Pinto PhD, MV, DACT; Dissertation Advisor Marco A. Coutinho da Silva PhD, MV, DACT; Academic Advisor Christopher Premanandan PhD, DVM, DACVP Copyright by Elizabeth Ann Coffman 2013 Abstract For breedinG manaGement and estrus synchronization, prostaGlandin F2α (PGF) is one of the most commonly utilized hormones to pharmacologically manipulate the equine estrous cycle. There is a general supposition a sinGle dose of PGF does not consistently induce luteolysis in the equine corpus luteum (CL) until at least five to six days after ovulation. This leads to the erroneous assumption that the early CL (before day five after ovulation) is refractory to the luteolytic effects of PGF. An experiment was desiGned to test the hypotheses that serial administration of PGF in early diestrus would induce a return to estrus similar to mares treated with a sinGle injection in mid diestrus, and fertility of the induced estrus for the two treatment groups would not differ. The specific objectives of the study were to evaluate the effects of early diestrus treatment by: 1) assessing the luteal function as reflected by hormone profile for concentration of plasma progesterone; 2) determininG the duration of interovulatory and treatment to ovulation intervals; 3) comparing of the number of pregnant mares at 14 days post- ovulation. The study consisted of a balanced crossover desiGn in which reproductively normal Quarter horse mares (n=10) were exposed to two treatments ii on consecutive reproductive cycles.
    [Show full text]